US stocks finished mixed after a volatile session on Wednesday, as investors weighed shifting winners and losers in the AI trade against policy risks for health insurers. The Nasdaq Composite rose 0.4% to 24,429, while the S&P 500 fell 0.2% to 7,323 and the Dow Jones Industrial Average lost 1.1% to 50,198. Nvidia dropped 2.9% despite strong results, with investors also looking ahead to Anthropic’s planned stock-market debut on Thursday.
The session’s other focal points included the US interest-rate outlook, retailer TJX’s results and a proposed federal audit of Medicare Advantage plans. The split among the major indexes reflected a market increasingly shaped by company-specific earnings and policy risks, rather than a single, broad AI trade.
Nvidia falls despite strong quarterly results
Nvidia reported quarterly revenue of $115.8 billion and earnings above market expectations. Management also raised its revenue-growth outlook for fiscal 2028 from 70% to 75%. Yet the shares fell 2.9% on Wednesday, suggesting the results did little to ease broader investor concerns.
Mark Malek, chief investment officer at Siebert Financial, said strong results from one company could not reverse weakening market breadth or offset the effect of higher interest rates. Minutes from the Federal Reserve’s October meeting showed policymakers continuing to prioritize inflation control, with discussion focused on whether the federal funds rate might need to rise and by how much. US Treasury yields near 5% are also raising the return hurdle for high-dividend stocks.
Investors are reassessing the AI trade, too. Rather than focusing only on which companies stand to benefit from AI investment, they are increasingly considering how the technology could pressure established business models. Malek said AI infrastructure providers may gain, while traditional software companies that rely on subscription revenue face greater competition.
Software shares weaken ahead of Anthropic listing
Anthropic is scheduled to begin trading on Thursday under the ticker ANT. As investors reconsider technology stocks amid changing risk appetite, the impact has varied across the sector. Salesforce fell 2.2%, Intuit lost 2.4% and ServiceNow declined 2.5%, as investors weighed the competitive threat from more capable automated agents.
The listing will give investors a fresh reference point for valuing AI companies, but Wednesday’s trading did not point to a broad technology rally. The Nasdaq advanced even as several software stocks fell, underscoring that the market is not treating AI’s potential benefits as evenly distributed across the sector.
TJX rises on results and holiday-season outlook
TJX Companies gained 8.1%, making it one of the session’s standout performers. Chief Executive Ernie Herman said third-quarter sales, profitability and earnings per share all exceeded the company’s expectations. Comparable sales rose 4%, and revenue at its Marmaxx division improved.
Herman said the results were ahead of plan and supported management’s expectation of stronger sales momentum in the fourth quarter. The company also expressed confidence in its holiday-season plans and said it had a good supply of merchandise.
Investors will next turn to Walmart, which is due to report fiscal 2027 third-quarter results before Thursday’s market open. Walmart shares edged down 0.1% on Wednesday.
Proposed CMS audit weighs on health insurers
UnitedHealth fell 10.2% on Wednesday, the steepest decline among Dow components, extending losses from the previous session. The Centers for Medicare & Medicaid Services (CMS) plans to recover Medicare Advantage overpayments dating as far back as payment year 2018, raising concerns about the potential financial impact on insurers.
CMS head Mehmet Oz has framed the proposal, called “CRUSH,” as an effort to combat fraud, waste and abuse in healthcare. Other companies with substantial Medicare Advantage businesses also fell sharply: Humana dropped 13.0%, while CVS Health lost 5.2%.
Oppenheimer analyst Michael Weiderhorn said the proposal revives an audit framework that a federal court rejected in September 2025. The expected increase in recoveries reflects a broader audit scope, though CMS could still revise the proposal before issuing a final rule. The plan may also face legal challenges similar to those brought against the earlier framework.
Weiderhorn said that even if the proposal is adopted in its current form and survives court review, insurers could account for the added costs in future bids rather than absorb a lasting hit to earnings. The proposal’s final scope, implementation and legal path remain unsettled, leaving investors focused on its potential impact on UnitedHealth, Humana and CVS.